Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Zealand To Cover Herceptin Breast Cancer Drug Despite Cost

This article was originally published in PharmAsia News

Executive Summary

Despite criticism the move would set a dangerous precedent, New Zealand's government said a 12-month course of a key breast cancer drug would be covered by the national health plan. The decision to cover Genentech's Herceptin (trastuzumab) would make the $109,000-a-year drug available to an estimated 300 women who get the disease every year. The opposition party said the action was tantamount to politicizing drug purchasing, since the nation's drug-buying agency had ruled against coverage. In New Zealand, about 40 new drugs are to be available within two years, each costing about as much as Herceptin. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts